ECIA · XBRL financial data

Encision financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ECIA's year ends in late March)

In thousands of dollars	FY 2020Mar 31, 2020	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025
Revenue	7,670	7,538	7,669	7,349	6,586	6,555
Cost of revenue	3,667	3,633	3,880	3,316	3,450	3,044
Gross profit	4,004	3,905	3,788	4,033	3,136	3,511
Research and development	748	570	918	816	622	593
General and administrative	1,318	1,377	1,381	1,487	1,521	1,401
Total operating expenses	4,160	3,967	4,383	4,335	3,777	3,683
Operating income (loss)	(156)	(62)	(595)	(303)	(641)	(172)
Interest expense	—	87	7	20	62	44
Other income (expense)	1	135	3	(2)	11	(4)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(198)	585	(66)	(324)	(692)	(220)
Earnings per share, basic USD per share	—	—	(0.01)	(0.03)	(0.06)	(0.02)
Earnings per share, diluted USD per share	—	—	(0.01)	(0.03)	(0.06)	(0.02)
Weighted average shares, basic thousands of shares	11,573	11,583	11,625	11,763	11,770	11,880
Weighted average shares, diluted thousands of shares	11,573	11,768	11,625	11,763	11,770	11,880

Fiscal years (ECIA's year ends in late March)

In thousands of dollars	FY 2020Mar 31, 2020	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025
Cash and cash equivalents	385	1,474	950	189	43	257
Accounts receivable	881	1,024	948	921	891	786
Inventory	1,626	1,445	1,584	1,899	1,402	1,483
Prepaid and other current assets	—	—	120	116	90	—
Total current assets	2,965	4,098	3,602	3,125	2,426	2,613
Property and equipment, net	207	266	189	303	254	245
Right-of-use asset	1,317	1,061	786	496	901	568
Total assets	4,737	5,659	4,792	4,134	3,811	3,671
Accounts payable	445	389	576	253	346	347
Total current liabilities	1,408	1,176	1,276	1,131	1,220	1,576
Lease liability, non-current	1,144	927	564	240	697	266
Total liabilities	2,553	2,856	2,047	1,639	1,984	2,020
Accumulated deficit	(22,048)	(21,464)	(21,529)	(21,853)	(22,545)	(22,765)
Total stockholders' equity	2,184	2,802	2,746	2,495	1,827	1,651
Total liabilities and equity	4,737	5,659	4,792	4,134	3,811	3,671
Common shares outstanding (cover page) thousands of shares	11,583	11,583	11,720	11,770	11,875	11,880

Fiscal years (ECIA's year ends in late March)

In thousands of dollars	FY 2020Mar 31, 2020	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025
Net income (loss)	(198)	585	(66)	(324)	(692)	(220)
Stock-based compensation	31	33	41	52	54	46
Depreciation and amortization	138	89	113	87	85	81
Net cash from operating activities	(229)	220	(444)	(861)	144	(55)
Purchases of property and equipment	48	30	18	173	12	54
Net cash from investing activities	(54)	(45)	(35)	(183)	(37)	(80)
Proceeds from issuing common stock	0	—	—	—	—	—
Net cash from financing activities	370	914	(45)	284	(254)	350

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Encision	72	1,528	(127)*	16.9M	0.6 quarters	Q2 FY26 10-QSep 30, 2025
Lucid Diagnostics	33,404	not reported	(11,297)*	203.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Beyond Air	5,509	1,768	(4,946)	957,631	2.0 quarters	Q1 FY27 10-QJun 30, 2026
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
InspireMD	15,149	1,771	(10,895)*	46.5M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Tenon Medical	1,677	1,279	(2,758)*	667,047	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Neuraxis	8,322	1,929	(1,030)*	12.6M	—	Q2 FY26 10-QJun 30, 2026
Nuwellis	3,922	1,969	(3,175)*	3.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.